TA negative (n = 55) | TA positive (n = 119) | P- value | ||
---|---|---|---|---|
Gender (n, %) | 0.018* | |||
Male | 13 (23.6) | 12 (10.1) | ||
Female | 42 (76.4) | 107 (89.9) | ||
Mean TSH* (SD) | 3.88 + 11.75 | 12.96 + 44.31 | 0.137 | |
Mean FT4 (S) | 13.59 + 3.79 | 13.49 + 5.12 | 0.904 | |
Levothyroxine Usage (n, %) | < 0.001* | |||
Yes | 8 (14.5) | 73 (61.3) | ||
No | 47 (85.5) | 46 (38.7) | ||
Presence of nodule (n, %) Yes No Heterogenicity (n, %) | 24 (43.6%) 31 (56.4%) | 31 (26.5%) 86 (73.5%) | 0.025* < 0.001* | |
Homogenous | 32 (62.7) | 13 (11.2) | ||
Heterogenous | 19 (37.3) | 103 (88.8) | ||
Echogenicity (n, %) | 0.427 | |||
Normal | 53 (96.4) | 111 (93.3) | ||
Hypoechoic | 1 (1.8) | 7 (5.9) | ||
Hyperechoic | 1 (1.8) | 1 (0.8) | ||
Vascularity (n, %) | < 0.001* | |||
Normal | 23 (63.9) | 11 (10.3) | ||
Hyper-vascular | 12 (33.3) | 95 (88.8) | ||
Hypo-vascular | 1 (2.8) | 1 (0.9) |